BioCentury
ARTICLE | Clinical News

IPH4102 regulatory update

September 15, 2014 7:00 AM UTC

The European Commission granted Orphan Drug designation to IPH4102 to treat cutaneous T cell lymphoma (CTCL). Next year, Innate plans to begin a Phase I trial with the humanized mAb against killer ce...